MA47504A - Composés et méthodes de traitement de l'angiocholite biliaire primitive - Google Patents

Composés et méthodes de traitement de l'angiocholite biliaire primitive

Info

Publication number
MA47504A
MA47504A MA047504A MA47504A MA47504A MA 47504 A MA47504 A MA 47504A MA 047504 A MA047504 A MA 047504A MA 47504 A MA47504 A MA 47504A MA 47504 A MA47504 A MA 47504A
Authority
MA
Morocco
Prior art keywords
angiocholitis
compounds
treatment methods
biliary
primitive
Prior art date
Application number
MA047504A
Other languages
English (en)
Inventor
Ronald J Christopher
Robert Mark Jones
Cheryl Geraldine Lassen
Que Liu
Original Assignee
Arena Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arena Pharm Inc filed Critical Arena Pharm Inc
Publication of MA47504A publication Critical patent/MA47504A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA047504A 2017-02-16 2018-02-16 Composés et méthodes de traitement de l'angiocholite biliaire primitive MA47504A (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762459916P 2017-02-16 2017-02-16
US201762502129P 2017-05-05 2017-05-05
US201762506906P 2017-05-16 2017-05-16

Publications (1)

Publication Number Publication Date
MA47504A true MA47504A (fr) 2019-12-25

Family

ID=61873875

Family Applications (1)

Application Number Title Priority Date Filing Date
MA047504A MA47504A (fr) 2017-02-16 2018-02-16 Composés et méthodes de traitement de l'angiocholite biliaire primitive

Country Status (10)

Country Link
US (2) US11534424B2 (fr)
EP (1) EP3582772A1 (fr)
JP (1) JP2020507611A (fr)
KR (1) KR20190116416A (fr)
CN (1) CN110520124A (fr)
AU (1) AU2018220521A1 (fr)
CA (1) CA3053418A1 (fr)
MA (1) MA47504A (fr)
MX (1) MX2019009841A (fr)
WO (1) WO2018151873A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5856980B2 (ja) 2010-01-27 2016-02-10 アリーナ ファーマシューティカルズ， インコーポレイテッド （Ｒ）−２−（７−（４−シクロペンチル−３−（トリフルオロメチル）ベンジルオキシ）−１，２，３，４−テトラヒドロシクロペンタ［ｂ］インドール−３−イル）酢酸およびその塩の調製のためのプロセス
PL3242666T3 (pl) 2015-01-06 2025-02-17 Arena Pharmaceuticals, Inc. Związek do zastosowania w leczeniu dolegliwości związanych z receptorem s1p1
BR112017027656B1 (pt) 2015-06-22 2023-12-05 Arena Pharmaceuticals, Inc. Hábito cristalino de placa livre de sal de l-arginina de ácido (r)-2-(7-(4- ciclopentil-3-(trifluorometil)benzilóxi)- 1,2,3,4-tetra-hidrociclo-penta[b]indol-3- il)acético, composição farmacêutica que o compreende, seus usos e método de preparação do mesmo
MX2019009841A (es) 2017-02-16 2020-01-30 Arena Pharm Inc Compuestos y metodos para el tratamiento de la colangitis biliar primaria.
MX2019009843A (es) 2017-02-16 2020-01-30 Arena Pharm Inc Compuestos y metodos para el tratamiento de la enfermedad inflamatoria intestinal con manifestaciones extraintestinales.
CA3102136A1 (fr) 2018-06-06 2019-12-12 Arena Pharmaceuticals, Inc. Methodes de traitement de troubles associes au recepteur s1p1<sb />
JP7265620B2 (ja) * 2018-10-03 2023-04-26 アリーナ ファーマシューティカルズ， インコーポレイテッド 強皮症の治療のための方法
CN118649163A (zh) * 2018-11-30 2024-09-17 艾尼纳制药公司 治疗与s1p1受体有关的病况的方法
AU2021205465A1 (en) * 2020-01-06 2022-07-14 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the S1P1 receptor
MX2022009776A (es) * 2020-02-10 2022-09-09 Genfit Tratamiento de la colangitis biliar primaria con elafibranor.
WO2025177319A2 (fr) * 2024-02-22 2025-08-28 Msn Laboratories Private Limited, R&D Center Formes à l'état solide de l-arginine, (3r)-7-[[4-cyclopentyl-3-(trifluorométhyl)phényl]méthoxy]-1,2,3,4-tétrahydrocyclopent[b]indole-3-acétate et leurs procédés de préparation

Family Cites Families (448)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL293572A (fr) 1962-06-07
CH478816A (de) 1965-10-22 1969-09-30 Ciba Geigy Verfahren zur Herstellung neuer N,N'-Di-(pyrimidyl-(4)-aminoalkyl)-diazacycloalkanen
CH480410A (de) 1967-01-09 1969-10-31 Geigy Ag J R Verfahren zur Herstellung von wasserlöslichen Azopyrimidinfarbstoffen
CA961052A (en) 1967-01-12 1975-01-14 Max Schellenbaum N-2-ethylhexyl-n'-aryl ureas and preparation containing them
US3608087A (en) 1968-06-21 1971-09-21 Merck & Co Inc Feed compositions
US3887329A (en) 1969-05-05 1975-06-03 Ciba Geigy Ag Hexamethyl phosphotriamide-dye compositions
BE756953A (fr) 1969-10-02 1971-04-01 Merck & Co Inc Potentialisation d'antibiotiques
US3686238A (en) 1970-01-19 1972-08-22 Syntex Corp Glycerol esterified with 2-naphthyl-acetic acids and fatty acids
US3852434A (en) 1970-09-11 1974-12-03 Merck & Co Inc Potentiation of ({31 ) cis-1,2-epoxypropyl)phosphonic acid and analogues thereof
US3690834A (en) 1971-01-11 1972-09-12 Syva Co Ligand determination with spin labeled compounds by receptor displacement
US3966744A (en) 1971-01-11 1976-06-29 Syva Company Spin labeled compounds
DE2106585A1 (de) 1971-02-11 1972-08-24 Farbenfabriken Bayer Ag, 5090 Leverkusen Aminothiodiazole und Thiodiazol-Azofarbstoffe
CH558137A (de) 1971-05-17 1975-01-31 Ciba Geigy Ag Mittel zur beeinflussung des pflanzenwachstums.
DE2226703A1 (de) 1972-05-25 1973-12-13 Schering Ag Neue tetrahydrocarbazolderivate und verfahren zu ihrer herstellung
US3966764A (en) 1972-07-10 1976-06-29 Syva Company Ligand determination of spin labeled compounds by receptor displacement-amphetamine analogs
US3849420A (en) 1972-10-20 1974-11-19 Dow Chemical Co Bis-(alkylthio-and alkylsulfonyl)-pentachloroquinolines
CH574206A5 (fr) 1972-11-16 1976-04-15 Ciba Geigy Ag
DE2340569C2 (de) 1973-08-10 1982-12-02 Bayer Ag, 5090 Leverkusen Azofarbstoffe
AT340933B (de) 1973-08-20 1978-01-10 Thomae Gmbh Dr K Verfahren zur herstellung neuer pyrimidinderivate und ihrer saureadditionssalze
DE2341925A1 (de) 1973-08-20 1975-03-06 Thomae Gmbh Dr K Neue pyrimidinderivate und verfahren zu ihrer herstellung
US4057559A (en) 1973-10-01 1977-11-08 American Home Products Corporation Carbazole acetic acid derivatives
US4101541A (en) 1973-12-21 1978-07-18 Ciba-Geigy Corporation 3-Cyano-1,2,4-thiadiazolyl-5-czo dyestuffs
CH584739A5 (fr) 1973-12-21 1977-02-15 Ciba Geigy Ag
FR2258841B1 (fr) 1974-01-29 1977-11-04 Ugine Kuhlmann
FR2306697A1 (fr) 1975-04-10 1976-11-05 Sogeras Nouvelles pyrimidines utilisables comme medicaments antidiabetiques et hypocholesterolemiants
US4139705A (en) 1977-05-20 1979-02-13 The Dow Chemical Company Pyrazolopyrimidines
US4189579A (en) 1977-05-20 1980-02-19 The Dow Chemical Company Aminoalkylthiopurines
DE2731264A1 (de) 1977-07-11 1979-02-01 Boehringer Mannheim Gmbh Neue 1-acyl-2-cyanaziridine, verfahren zu deren herstellung und diese verbindungen enthaltende pharmazeutische zubereitungen
JPS6038696B2 (ja) 1977-12-09 1985-09-02 コニカ株式会社 ハロゲン化銀カラ−写真感光材料
US4242507A (en) 1978-02-23 1980-12-30 Fujisawa Pharmaceutical Co., Ltd. Sulfonic acid esters
DE2831580C2 (de) 1978-07-18 1980-09-18 Boehringer Mannheim Gmbh, 6800 Mannheim Verfahren und Reagens zur Bestimmung von Glycerin
DE2831850A1 (de) 1978-07-20 1980-02-07 Basf Ag N-arylsulfonylpyrrole, ihre herstellung und diese enthaltende therapeutische mittel
DE2906603A1 (de) 1979-02-21 1980-09-04 Boehringer Mannheim Gmbh N-substituierte aziridin-2-carbonsaeurederivate, verfahren zu deren herstellung sowie diese substanzen enthaltende arzneimittel
US4343804A (en) 1979-03-26 1982-08-10 A. H. Robins Company, Inc. 4-Amino-3-quinolinecarboxylic acids and esters-antisecretory anti-ulcer compounds
EP0053678A1 (fr) 1980-12-05 1982-06-16 BASF Aktiengesellschaft Amino-5-phényl-1-cyano-4-pyrazoles, herbicides les contenant, leur procédé de préparation et leur application comme herbicides
DOP1981004033A (es) 1980-12-23 1990-12-29 Ciba Geigy Ag Procedimiento para proteger plantas de cultivo de la accion fitotoxica de herbicidas.
US4476248A (en) 1983-02-28 1984-10-09 The Upjohn Company Crystallization of ibuprofen
DE3334455A1 (de) 1983-03-04 1984-09-06 Bayer Ag, 5090 Leverkusen Guanidin - derivate
US4612376A (en) 1983-03-25 1986-09-16 Fujisawa Pharmaceutical Co., Ltd. Substituted-3,4-dihydro-4-(2,4,6-trimethoxyphenylimino)-2(1H)-pyrimidones useful as cardiotonic, antihypertensive, cerebrovascular vasodilator and anti-platelet agent
ZA848275B (en) 1983-12-28 1985-08-28 Degussa New piridine-2-ethers or pyridine-2-thioethers having a nitrogen-containing cycloaliphatic ring
DE3406329A1 (de) 1984-02-22 1985-08-22 Merck Patent Gmbh, 6100 Darmstadt Pyridone
DE3601196A1 (de) 1986-01-17 1987-07-23 Merck Patent Gmbh 1,4-dihydropyridine
US4810699A (en) 1987-02-20 1989-03-07 American Home Products Corporation Substituted 1,3,4,9-tetrahydropyrano[3,4,-b]indole-1-acetic acids, pharmaceutical compositions containing them, and methods for treating inflammatory conditions and for analgesic purposes using them
US4782076A (en) 1988-03-01 1988-11-01 American Home Products Corporation Substituted 2,3,4,9-tetrahydro-1H-carbazole-1-acetic acid derivatives, composition and use
PT95692A (pt) 1989-10-27 1991-09-13 American Home Prod Processo para a preparacao de derivados de acidos indole-,indeno-,piranoindole- e tetra-hidrocarbazole-alcanoicos, ou quais sao uteis como inibidores de pla2 e da lipoxigenase
US5221678A (en) 1990-07-26 1993-06-22 Merck Frosst Canada, Inc. (quinolin-2-ylmethoxy)tetrahydrocarbazoles as inhibitors of the biosynthesis of leukotrienes
DE4208254A1 (de) 1992-03-14 1993-09-16 Hoechst Ag Substituierte pyrimidine, verfahren zu ihrer herstellung und ihre verwendung als schaedlingsbekaempfungsmittel und fungizid
TW237456B (fr) 1992-04-09 1995-01-01 Ciba Geigy
FR2692575B1 (fr) 1992-06-23 1995-06-30 Sanofi Elf Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
DE4241632A1 (de) 1992-12-10 1994-06-16 Thomae Gmbh Dr K Carbonsäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
US5998499A (en) 1994-03-25 1999-12-07 Dentsply G.M.B.H. Liquid crystalline (meth)acrylate compounds, composition and method
BR9407799A (pt) 1993-10-12 1997-05-06 Du Pont Merck Pharma Composição de matéria método de tratamento e composição farmaceutica
TW530047B (en) 1994-06-08 2003-05-01 Pfizer Corticotropin releasing factor antagonists
PT781766E (pt) 1994-09-09 2004-07-30 Nippon Shinyaku Co Ltd Derivado heterociclico e medicamento
US5691364A (en) 1995-03-10 1997-11-25 Berlex Laboratories, Inc. Benzamidine derivatives and their use as anti-coagulants
US6403599B1 (en) 1995-11-08 2002-06-11 Pfizer Inc Corticotropin releasing factor antagonists
US6956047B1 (en) 1995-06-06 2005-10-18 Pfizer Inc. Corticotropin releasing factor antagonists
KR0169813B1 (ko) 1995-07-12 1999-01-15 김종인 4-아미노-3-아실나프티리딘 유도체
US5849759A (en) 1995-12-08 1998-12-15 Berlex Laboratories, Inc. Naphthyl-substituted benzimidazole derivatives as anti-coagulants
US5948786A (en) 1996-04-12 1999-09-07 Sumitomo Pharmaceuticals Company, Limited Piperidinylpyrimidine derivatives
US6060478A (en) 1996-07-24 2000-05-09 Dupont Pharmaceuticals Azolo triazines and pyrimidines
US5776967A (en) 1996-07-26 1998-07-07 American Home Products Corporation Pyranoindole inhibitors of COX--2
AR008789A1 (es) 1996-07-31 2000-02-23 Bayer Corp Piridinas y bifenilos substituidos
US5830911A (en) 1996-08-14 1998-11-03 American Home Products Corporation Pyranoindole and tetrahydrocarbazole inhibitors of COX-2
US6008234A (en) 1996-09-12 1999-12-28 Berlex Laboratories, Inc. Benzamidine derivatives substituted by cyclic amino acid and cyclic hydroxy acid derivatives and their use as anti-coagulants
NL1010018C2 (nl) 1997-09-09 1999-03-10 Duphar Int Res Chinoline en chinazoline derivaten met corticotropine releasing factor (CRF) antagonistische werking.
GB9722361D0 (en) * 1997-10-24 1997-12-17 Pharma Nord Uk Ltd Pharmaceutical formulation for treating liver disorders
US6861448B2 (en) 1998-01-14 2005-03-01 Virtual Drug Development, Inc. NAD synthetase inhibitors and uses thereof
US6187777B1 (en) 1998-02-06 2001-02-13 Amgen Inc. Compounds and methods which modulate feeding behavior and related diseases
EP1105394A1 (fr) 1998-08-21 2001-06-13 Du Pont Pharmaceuticals Company Isoxazolo 4,5-d]pyrimidines comme antagonistes du crf
US6239126B1 (en) 1998-12-17 2001-05-29 American Home Products Corporation Arylpiperidine and aryl-1,2,5,6-tetra-hydropyridine urea derivatives
HUP0104987A3 (en) 1998-12-18 2002-09-30 Axys Pharmaceuticals Inc South Benzimidazole or indole derivatives protease inhibitors, and pharmaceutical compositions containing them
CZ27399A3 (cs) 1999-01-26 2000-08-16 Ústav Experimentální Botaniky Av Čr Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv
US6267985B1 (en) 1999-06-30 2001-07-31 Lipocine Inc. Clear oil-containing pharmaceutical compositions
AU761453B2 (en) 1999-03-17 2003-06-05 Astrazeneca Ab Amide derivatives
YU72201A (sh) 1999-04-28 2005-07-19 Aventis Pharma Deutschland Gmbh. Derivati di-aril kiseline kao ppar receptorski ligandi
JP2003509428A (ja) 1999-09-17 2003-03-11 アボツト・ゲー・エム・ベー・ハー・ウント・コンパニー・カーゲー 治療薬としてのピラゾロピリミジン
US6921763B2 (en) 1999-09-17 2005-07-26 Abbott Laboratories Pyrazolopyrimidines as therapeutic agents
US6414002B1 (en) 1999-09-22 2002-07-02 Bristol-Myers Squibb Company Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
TR200200763T2 (tr) 1999-09-24 2003-09-22 Janssen Pharmaceutica N.V. Antiviral bileşimler
PL354784A1 (en) 1999-09-30 2004-02-23 Neurogen Corporation Certain alkylene diamine-substituted heterocycles
ES2277855T3 (es) 1999-09-30 2007-08-01 Neurogen Corporation Pirazolo-(1,5-a)-1,5-pirimidinas y pirazolo-(1,5-a)-1,3,5-triazinas amino sustituidas.
CA2379585C (fr) 1999-09-30 2006-06-20 James W. Darrow Pyrazolo[1,5,-a]-1,5-pyrimidines a substitution alkylene-diamine et pyrazolo[1,5-a]-1,3,5-triazines
DE19947154A1 (de) 1999-10-01 2001-10-04 Bayer Ag Substituierte 2-Thio-3,5-dicyano-4-aryl-6-aminopyridine und ihre Verwendung
US6887870B1 (en) 1999-10-12 2005-05-03 Bristol-Myers Squibb Company Heterocyclic sodium/proton exchange inhibitors and method
GR990100388A (el) 1999-11-09 2001-07-31 Φαρμακευτικος συνδυασμος αποτελουμενος απο χωριστες δοσολογικες μορφες σε συσκευασια συμμορφωσης (compliance package) ενος αναστολεα της αναγωγασης του υδροξυ-μεθυλο-γλουταρυλο συνενζυμου α (στατινης, statin) και ενος παραγωγου του φιμπρικου οξεος....
JP2003518128A (ja) 1999-12-22 2003-06-03 メルク フロスト カナダ アンド カンパニー タンパク質チロシンホスファターゼ１ｂ（ｐｔｐ−１ｂ）のインヒビターとなる芳香族ホスホネート
DE19962936A1 (de) 1999-12-24 2001-06-28 Bayer Ag Neue beta-Aminosäureverbindungen als Integrinantagonisten
IL150337A0 (en) 1999-12-30 2002-12-01 Lundbeck & Co As H Phenylpiperazinyl derivatives
HUP0204272A3 (en) 2000-01-18 2005-03-29 Pfizer Prod Inc Corticotropin releasing factor antagonists, pharmaceutical compositions containing them and their use
CA2399136A1 (fr) 2000-02-09 2001-08-16 Hideo Kato Derives de 1h-imidazopyridine
JP2003523418A (ja) 2000-02-15 2003-08-05 フオスター・ミラー・インコーポレイテツド 揮発性有機成分を含まない放射硬化性樹脂組成物
US6569879B2 (en) 2000-02-18 2003-05-27 Merck & Co., Inc. Aryloxyacetic acids for diabetes and lipid disorders
JP2003523336A (ja) 2000-02-18 2003-08-05 メルク エンド カムパニー インコーポレーテッド 糖尿病及び脂質障害のためのアリールオキシ酢酸
WO2001062233A2 (fr) 2000-02-25 2001-08-30 F. Hoffmann La Roche Ag Modulateurs de recepteurs de l'adenosine
CN1440283A (zh) 2000-04-12 2003-09-03 诺瓦提斯公司 有机化合物的联合形式
AU782948B2 (en) 2000-05-08 2005-09-15 Janssen Pharmaceutica N.V. Prodrugs of HIV replication inhibiting pyrimidines
DE10024319A1 (de) 2000-05-17 2001-11-22 Merck Patent Gmbh Bisacylguanidine
US6440960B1 (en) 2000-05-18 2002-08-27 Neurocrine Biosciences, Inc. CRF receptor antagonists and methods relating thereto
EP1289964B1 (fr) 2000-05-25 2004-10-20 F. Hoffmann-La Roche Ag 1-aminoalkyle-lactames substitues et leur utilisation en tant qu'antagonistes de recepteur muscarinique
US6620821B2 (en) 2000-06-15 2003-09-16 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
JP2004501191A (ja) 2000-06-28 2004-01-15 テバ　ファーマシューティカル　インダストリーズ　リミティド カルベジロール
EP1294704A1 (fr) 2000-06-29 2003-03-26 Abbott Laboratories Derives d'aryle phenylheterocyclyle sulfures et leur utilisation en tant qu'agents immunosuppresseurs anti-inflammatoires inhibant l'adherence cellulaire
AR028782A1 (es) 2000-07-05 2003-05-21 Taisho Pharmaceutical Co Ltd Derivados heterociclicos tetrahidropiridino o piperidino
US6444685B1 (en) 2000-07-17 2002-09-03 Wyeth N-(4-sulfonylaryl)Cyclylamine 2-hydroxyethylamines as beta-3 adrenergic receptor agonists
CA2415899A1 (fr) 2000-07-18 2003-01-13 Chikashi Saitoh Medicament comprenant un derive de dicyanopyridine
US6410583B1 (en) 2000-07-25 2002-06-25 Merck Frosst Canada & Co. Cyclopentanoindoles, compositions containing such compounds and methods of treatment
AU7705601A (en) 2000-07-25 2002-02-05 Merck & Co Inc N-substituted indoles useful in the treatment of diabetes
AU2001284417A1 (en) 2000-09-05 2002-03-22 Taisho Pharmaceutical Co. Ltd. Hair growth stimulants
ATE367802T1 (de) 2000-09-20 2007-08-15 Jagotec Ag Verfahren zur sprühtrocknung von zusammensetzungen enthaltend fenofibrat
US7276249B2 (en) 2002-05-24 2007-10-02 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
US20030224058A1 (en) 2002-05-24 2003-12-04 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
PE20020507A1 (es) 2000-10-17 2002-06-25 Schering Corp Compuestos no-imidazoles como antagonistas del receptor histamina h3
AU2002223626A1 (en) 2000-10-20 2002-04-29 Novartis Ag Combinations of a thyromimetic compound and a statin
CN100525768C (zh) 2000-10-23 2009-08-12 史密丝克莱恩比彻姆公司 新化合物
AU2002248221B2 (en) 2000-10-31 2006-08-17 Merck & Co., Inc. Benzopyrancarboxylic acid derivatives for the treatment of diabetes and lipid disorders
DE60126134T2 (de) 2000-11-03 2007-10-18 Neurocrine Biosciences, Inc., San Diego CRF-Rezeptorantagonisten und Verfahren, die damit in Beziehung stehen
US20020058026A1 (en) 2000-11-13 2002-05-16 Milton Hammerly HMG CoA reductase inhibitor medications combined wih CoEnzyme Q-10
WO2002039987A2 (fr) 2000-11-14 2002-05-23 Neurosearch A/S Mise en oeuvre de bloquants des canaux anioniques des parasites de la malaria pour traiter cette maladie
UA77165C2 (en) 2000-11-17 2006-11-15 Lilly Co Eli (n)-((s)-2-hydroxy-3-methyl-butyryl)-1-(l-alaninyl)-(s)-1-amino-3-methyl-4,5,6,7-tetrahydro-2h-3-benzazepin-2-one dihydrate, processes for manufacturing and pharmaceutical composition
EP1340749A4 (fr) 2000-11-17 2007-09-05 Takeda Pharmaceutical Derives d'isoxazole
CA2448729A1 (fr) 2000-11-20 2002-05-23 Biovitrum Ab Composes heterocycliques substitues par des groupes piperazinyle et piperidyle
EP1338651B9 (fr) 2000-12-01 2007-05-09 Astellas Pharma Inc. Procede de depistage d'un remede
US20020137755A1 (en) 2000-12-04 2002-09-26 Bilodeau Mark T. Tyrosine kinase inhibitors
US6545016B1 (en) 2000-12-08 2003-04-08 3M Innovative Properties Company Amide substituted imidazopyridines
US20020107262A1 (en) 2000-12-08 2002-08-08 3M Innovative Properties Company Substituted imidazopyridines
US6545017B1 (en) 2000-12-08 2003-04-08 3M Innovative Properties Company Urea substituted imidazopyridines
US6525064B1 (en) 2000-12-08 2003-02-25 3M Innovative Properties Company Sulfonamido substituted imidazopyridines
WO2002050071A1 (fr) 2000-12-21 2002-06-27 Bristol-Myers Squibb Company Inhibiteurs thiazolyl des tyrosine kinases de la famille tec
DK1355644T3 (da) 2001-01-26 2006-10-23 Schering Corp Anvendelse af substituerede azetidinonforbindelser til behandling af sitosterolæmi
JP2004529100A (ja) 2001-01-30 2004-09-24 ユニバーシティ オブ バージニア パテント ファウンデーション スフィンゴシン−１−ホスフェートレセプターのアゴニストおよびアンタゴニスト
EP1357908A4 (fr) 2001-01-30 2009-07-15 Merck & Co Inc Acyl-sulfamides pour le traitement de l'obesite, du diabete et des troubles lipidiques
CN100439370C (zh) 2001-02-08 2008-12-03 记忆药物公司 作为磷酸二酯酶4抑制剂的三氟甲基嘌呤
CA2437118A1 (fr) 2001-02-09 2002-08-22 Merck & Co., Inc. Acides 2-aryloxy-2-arylalcanoiques utilises pour le traitement du diabetes et des troubles lipidiques
DE10110754A1 (de) 2001-03-07 2002-09-19 Bayer Ag Substituierte 2-Thio-3,5-dicyano-4-aryl-6-aminopyridine und ihre Verwendung
WO2002072101A1 (fr) 2001-03-13 2002-09-19 Bristol-Myers Squibb Pharma Company Ligand du recepteur de la corticoliberine, son enantiomere et ses sels pharmaceutiquement acceptables
WO2002079131A1 (fr) 2001-03-29 2002-10-10 Kansai Research Institute, Inc. Compose optiquement actif et composition de resine photosensible
WO2002081454A1 (fr) 2001-04-09 2002-10-17 Dr. Reddy's Laboratories Ltd. Derives d'acides aryliques et leur utilisation en medecine, procede de preparation de ces derives et compositions pharmaceutiques contenant lesdits derives
CN1293072C (zh) 2001-04-20 2007-01-03 惠氏公司 作为5－羟色胺－6配体的杂环基氧基－、－硫代－和－氨基吲哚衍生物
ES2316613T3 (es) 2001-05-10 2009-04-16 Ono Pharmaceutical Co., Ltd. Derivados de acido crboxilico y composiciones farmaceuticas que contienen los mismos como ingrediente activo.
DK1397351T3 (da) 2001-06-01 2010-01-18 Hoffmann La Roche Pyrimidin-, triazin- og pyrazinderivater som glutamatreceptorer
CA2450934A1 (fr) 2001-06-19 2002-12-27 Marco Dodier Inhibiteurs pyrimidine de la phosphodiesterase (pde) 7
US6825198B2 (en) 2001-06-21 2004-11-30 Pfizer Inc 5-HT receptor ligands and uses thereof
AU2002316421B2 (en) 2001-06-26 2008-05-15 Bristol-Myers Squibb Company N-heterocyclic inhibitors of TNF-ALPHA expression
UA74912C2 (en) 2001-07-06 2006-02-15 Merck & Co Inc Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes
GB0117899D0 (en) 2001-07-23 2001-09-12 Astrazeneca Ab Chemical compounds
WO2003026661A1 (fr) 2001-09-14 2003-04-03 Yamanouchi Pharmaceutical Co., Ltd. Accelerateur de secretion de l'insuline et nouveau derive de pyrimidine
CA2461212C (fr) 2001-09-27 2010-08-17 Kyorin Pharmaceutical Co., Ltd. Derive de sulfure de diaryle, sels correspondant et agents immunosuppresseur utilisant ces derives
EP1438048A1 (fr) 2001-10-18 2004-07-21 Boehringer Ingelheim Pharmaceuticals Inc. Composes d'uree benzo fusionnes 1,4-disubstitues utilises comme inhibiteurs des cytokines
GB0229931D0 (en) 2002-12-21 2003-01-29 Astrazeneca Ab Therapeutic agents
SE0104334D0 (sv) 2001-12-19 2001-12-19 Astrazeneca Ab Therapeutic agents
WO2003059378A2 (fr) 2001-12-29 2003-07-24 Novo Nordisk A/S Utilisation combinee d'un compose glp-1 et d'un autre medicament pour traiter la dyslipidemie
WO2003057689A1 (fr) 2002-01-02 2003-07-17 Fujisawa Pharmaceutical Co., Ltd. Composes aminopyrimidine, procedes de preparation de ces composes et compositions pharmaceutiques les contenant
US20070225351A1 (en) 2002-01-11 2007-09-27 Lippa Arnold S Methods and compositions for controlling body weight and appetite
JP4430941B2 (ja) 2002-01-18 2010-03-10 メルク エンド カムパニー インコーポレーテッド Ｅｄｇ受容体作動薬
JP2005516967A (ja) 2002-01-18 2005-06-09 ザ ジェネティクス カンパニー インコーポレーティッド β−セクレターゼインヒビター
WO2003061567A2 (fr) 2002-01-18 2003-07-31 Merck & Co., Inc. Antagonistes sélectifs du récepteur s1p1/edg1
GB0201850D0 (en) 2002-01-26 2002-03-13 Astrazeneca Ab Therapeutic treatment
WO2003074008A2 (fr) 2002-03-01 2003-09-12 Merck & Co., Inc. Aminoalkylphosphonates et composes associes utilises en tant qu'agonistes du recepteur edg
JP2005531506A (ja) 2002-03-01 2005-10-20 メルク　エンド　カムパニー　インコーポレーテッド Ｅｄｇ受容体作動薬としてのアミノアルキルホスホネートおよび関連化合物
ATE507210T1 (de) 2002-03-07 2011-05-15 X Ceptor Therapeutics Inc Chinazolinon modulatoren von nukleinrezeptoren
US7731985B2 (en) 2002-03-15 2010-06-08 Ciba Specialty Chemicals Corporation 4-aminopyrimidines and their use for the antimicrobial treatment of surfaces
TW200810743A (en) 2002-03-22 2008-03-01 Novartis Ag Combination of organic compounds
AU2003225027A1 (en) 2002-04-16 2003-11-03 Merck And Co., Inc. Combination therapy using a ppar alpha/gamma agonist
AU2003222786A1 (en) 2002-04-18 2003-10-27 Ucb, S.A. Chemical compounds with dual activity, processes for their preparation and pharmaceutical compositions
DE10219435A1 (de) 2002-05-02 2003-11-13 Bayer Cropscience Ag Substituierte Pyrazolo-pyrimidin-4-one
WO2003094845A2 (fr) 2002-05-08 2003-11-20 Bristol-Myers Squibb Company Ligands du recepteur de la thyroide a base de pyridine
US7057046B2 (en) 2002-05-20 2006-06-06 Bristol-Myers Squibb Company Lactam glycogen phosphorylase inhibitors and method of use
WO2003103640A1 (fr) 2002-06-10 2003-12-18 Elan Pharma International, Ltd Formulations nanoparticulaires comprenant des derives d'un inhibiteur de la hmg coa-reductase (≤statines≥), nouvelles combinaisons associees et production de ces compositions pharmaceutiques
CA2488617A1 (fr) 2002-06-10 2003-12-18 Eugene R. Cooper Preparation de sterols nanoparticulaires et nouvelles combinaisons de sterols
AR040241A1 (es) 2002-06-10 2005-03-23 Merck & Co Inc Inhibidores de la 11-beta-hidroxiesteroide deshidrogrenasa 1 para el tratamiento de la diabetes obesidad y dislipidemia
JP4533134B2 (ja) 2002-06-10 2010-09-01 エラン ファーマ インターナショナル，リミティド ナノ粒子ポリコサノール製剤および新規なポリコサノールの組合せ
WO2003105763A2 (fr) 2002-06-14 2003-12-24 Amylin Pharmaceuticals, Inc. Prevention et/ou traitement de maladie enterique inflammatoire au moyen de peptides yy ou d'antagonistes de peptides yy
JP2005533058A (ja) 2002-06-17 2005-11-04 メルク　エンド　カムパニー　インコーポレーテッド Ｅｄｇ受容体アゴニストとしての１−（（５−アリール−１，２，４−オキサジアゾール−３−イル）ベンジル）アゼチジン−３−カルボキシラートおよび１−（（５−アリール−１，２，４−オキサジアゾール−３−イル）ベンジル）ピロリジン−３−カルボキシラート
DE10226943A1 (de) 2002-06-17 2004-01-08 Bayer Ag Phenylaminopyrimidine und ihre Verwendung
GB0214254D0 (en) 2002-06-20 2002-07-31 Glaxo Group Ltd Chemical compounds
SE0201980D0 (sv) 2002-06-24 2002-06-24 Astrazeneca Ab Novel compounds
SE0201976D0 (sv) 2002-06-24 2002-06-24 Astrazeneca Ab Novel compounds
US20060014717A1 (en) 2002-06-28 2006-01-19 Glykos Finland Oy Therapeutic compositions for use in prophylaxis or treatment of diarrheas
US7071210B2 (en) 2002-07-02 2006-07-04 Pfizer Inc. CETP inhibitors in combination with antihypertensive agents and uses thereof
US20040053842A1 (en) 2002-07-02 2004-03-18 Pfizer Inc. Methods of treatment with CETP inhibitors and antihypertensive agents
AU2003252478A1 (en) 2002-07-10 2004-02-02 Ono Pharmaceutical Co., Ltd. Ccr4 antagonist and medicinal use thereof
AU2003261204A1 (en) 2002-07-23 2004-02-09 Smithkline Beecham Corporation Pyrazolopyrimidines as kinase inhibitors
JP2006514918A (ja) 2002-07-23 2006-05-18 スミスクライン ビーチャム コーポレーション キナーゼインヒビターとしてのピラゾロピリミジン
AU2003254053A1 (en) 2002-07-23 2004-02-09 Smithkline Beecham Corporation Pyrazolopyrimidines as protein kinase inhibitors
US20060105445A1 (en) 2002-07-29 2006-05-18 Klaus Godl Medium and method for enriching, purifying or depleting atp binding proteins from a pool of proteins
US7241790B2 (en) 2002-07-30 2007-07-10 University Of Virginia Patent Foundation Compounds active in spinigosine 1-phosphate signaling
EP1539137B1 (fr) 2002-07-30 2010-05-26 Merck Sharp & Dohme Corp. Composes ppar alpha selectifs destines au traitement de la dyslipidemie et autres troubles lipidiques
JP4475406B2 (ja) 2002-07-30 2010-06-09 メルク・シャープ・エンド・ドーム・コーポレイション 異常脂血症および他の脂質障害の治療用のＰＰＡＲα選択的化合物
AR041191A1 (es) 2002-08-08 2005-05-04 Amgen Inc Ligandos del receptor vanilloide y su uso en tratamientos
DE10237722A1 (de) 2002-08-17 2004-08-19 Aventis Pharma Deutschland Gmbh Indol- oder Benzimidazolderivate zur Modulation der IKappaB-Kinase
US20060167045A1 (en) 2002-08-21 2006-07-27 Joanne Waldstreicher Combination therapy using a dual ppar alpha/gamma agonist and an angiotensin II type I receptor antagonist
CN100457730C (zh) 2002-08-29 2009-02-04 默克公司 具有抗糖尿病活性的吲哚化合物
EP1546142A4 (fr) 2002-08-29 2007-10-17 Merck & Co Inc Indoles presentant un effet antidiabetique
EP1538217A4 (fr) 2002-09-11 2006-09-27 Astellas Pharma Inc Procede de criblage d'un amplificateur de la teneur en insuline
JP2006510597A (ja) 2002-09-27 2006-03-30 メルク　エンド　カムパニー　インコーポレーテッド 置換ピリミジン類
US7067658B2 (en) 2002-09-30 2006-06-27 Bristol-Myers Squibb Company Pyridino and pyrimidino pyrazinones
AU2003282679A1 (en) 2002-10-04 2004-05-04 Arena Pharmaceuticals, Inc. Hydroxypyrazoles for use against metabolic-related disorders
AU2003284111A1 (en) 2002-10-09 2004-05-04 Genaissance Pharmaceuticals, Inc. Itgb3 gene haplotypes and atorvastatin dose effects on hdl cholesterol
EP1551842A1 (fr) 2002-10-15 2005-07-13 Smithkline Beecham Corporation Composes de pyradazine utiles comme inhibiteurs de gsk-3
US7129239B2 (en) 2002-10-28 2006-10-31 Pfizer Inc. Purine compounds and uses thereof
CA2503715A1 (fr) 2002-10-30 2004-05-21 Merck & Co., Inc. Inhibiteurs de kinase
CA2505322A1 (fr) 2002-11-08 2004-05-21 Takeda Pharmaceutical Company Limited Agent de controle de la fonction recepteur
US7098235B2 (en) 2002-11-14 2006-08-29 Bristol-Myers Squibb Co. Triglyceride and triglyceride-like prodrugs of glycogen phosphorylase inhibiting compounds
US20040110241A1 (en) 2002-12-06 2004-06-10 Segal Mark S. Materials and methods for monitoring vascular endothelial function
JO2397B1 (en) 2002-12-20 2007-06-17 ميرك شارب اند دوم كوربوريشن Terazol derivatives as beta-hydroxy steroid dihydrogenase-1 inhibitors
DE60335827D1 (de) 2002-12-20 2011-03-03 Merck Sharp & Dohme 1-(amino)indane als edg-rezeptoragonisten
EP1578715B1 (fr) 2002-12-20 2011-03-02 Bayer Pharmaceuticals Corporation Derives d'acide acetique d'indane et leur utilisation en tant qu'agents pharmaceutiques et intermediaires, et procede de preparation correspondant
WO2004058727A1 (fr) 2002-12-20 2004-07-15 Bayer Pharmaceuticals Corporation 3,5-dihydro-4-h-imidazol-4-ones substitues utilises dans le traitement de l'obesite
GB0230020D0 (en) 2002-12-23 2003-01-29 Syngenta Ltd Fungicides
GB0230021D0 (en) 2002-12-23 2003-01-29 Syngenta Ltd Fungicides
MXPA05007485A (es) 2003-01-14 2006-01-30 Arena Pharm Inc Derivados de arilo y heteroarilo 1,2,3-trisubstituidos como moduladores del metabolismo y la profilaxis y tratamiento de trastornos relacionados con ello tales como diabetes e hiperglicemia.
WO2004062665A1 (fr) 2003-01-16 2004-07-29 Sb Pharmco Puerto Rico Inc Derives pyrrolo[2,3-b]pyridine a substitution heteroaryle utilises comme antagonistes des recepteurs du crf
AU2004207444B2 (en) 2003-01-17 2008-07-31 Merck & Co., Inc. N-cyclohexylaminocarbonyl benzenesulfonamide derivatives
GB0301259D0 (en) 2003-01-20 2003-02-19 Novartis Ag Organic compounds
PL378134A1 (pl) 2003-02-11 2006-03-06 Irm Llc Nowe pochodne bicykliczne i kompozycje farmaceutyczne zawierające pochodne bicykliczne
TW200418829A (en) 2003-02-14 2004-10-01 Avanir Pharmaceutics Inhibitors of macrophage migration inhibitory factor and methods for identifying the same
BRPI0407658A (pt) 2003-02-18 2006-02-21 Kyorin Seiyaku Kk derivados de ácido aminofosfÈnico, seus sais e hidratos que atuam como moduladores de receptor de s1p e agente farmacêutico
WO2004076413A2 (fr) 2003-02-24 2004-09-10 Arena Pharmaceuticals, Inc. Derives d'aryle et heteroaryle susbtitues tenant lieu de modulateurs du metabolisme du glucose et prophylaxie et traitement de troubles associes
JP2006521344A (ja) 2003-03-28 2006-09-21 ファイザー・プロダクツ・インク アテローム性動脈硬化症および肥満の治療のためのｃｅｔｐ阻害剤としての１，２，４−置換１，２，３，４−テトラヒドロ−および１，２−ジヒドロ−キノリンおよび１，２，３，４−テトラヒドロ−キノキサリン誘導体
MXPA05011597A (es) 2003-04-30 2005-12-15 Novartis Ag Derivados de aminopropanol como moduladores del receptor 1-fosfato de esfingosina.
US7329680B2 (en) 2003-04-30 2008-02-12 The Institute For Pharmaceutical Discovery, Llc Heterocycle substituted carboxylic acids
CN1777575B (zh) 2003-04-30 2010-05-12 诺瓦提斯公司 作为1-磷酸-鞘氨醇受体调节剂的氨基-丙醇衍生物
TWI494102B (zh) 2003-05-02 2015-08-01 Japan Tobacco Inc 包含ｓ-〔２（〔〔１-（２-乙基丁基）環己基〕羰基〕胺基）苯基〕２-甲基丙烷硫酯及ｈｍｇ輔酶ａ還原酶抑制劑之組合
SE0301368D0 (sv) 2003-05-09 2003-05-09 Astrazeneca Ab Chemical compounds
US7083933B1 (en) 2003-05-09 2006-08-01 Prosidion Limited Methods for identification of modulators of OSGPR116 activity
AU2004240586A1 (en) 2003-05-15 2004-12-02 Merck & Co., Inc. 3-(2-amino-1-azacyclyl)-5-aryl-1,2,4-oxadiazoles as S1P receptor agonists
WO2004104205A2 (fr) 2003-05-16 2004-12-02 Merck & Co., Inc. Preparation enzymatique d'esters d'indole chiraux
CL2004001120A1 (es) 2003-05-19 2005-04-15 Irm Llc Compuestos derivados de amina sustituidas con heterociclos, inmunosupresores; composicion farmaceutica; y uso para tratar enfermedades mediadas por interacciones de linfocito, tales como enfermedades autoinmunes, inflamatorias, infecciosas, cancer.
MY150088A (en) 2003-05-19 2013-11-29 Irm Llc Immunosuppressant compounds and compositions
EP1644367B1 (fr) 2003-05-19 2015-10-14 Novartis AG Compositions et composes immunosuppresseurs
MXPA05012459A (es) 2003-05-19 2006-02-22 Irm Llc Compuestos y composiciones inmunosupresoras.
US6987118B2 (en) 2003-05-21 2006-01-17 Pfizer Inc. Tetrahydroisoquinoline derivatives as PPAR-alpha activators
EP1635773A2 (fr) 2003-06-06 2006-03-22 Merck &amp; Co., Inc. (a New Jersey corp.) Polytherapie pour le traitement de l'hypertension
AU2003902882A0 (en) 2003-06-10 2003-06-26 Fujisawa Pharmaceutical Co., Ltd. Piperidyl derivatives
GB0313612D0 (en) 2003-06-12 2003-07-16 Novartis Ag Organic compounds
AR045047A1 (es) 2003-07-11 2005-10-12 Arena Pharm Inc Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
RS20060018A (sr) 2003-07-14 2007-12-31 Arena Pharmaceuticals Inc., Derivati spojenih arila i heteroarila kao modulatori metabolizma u profilaksi i lečenju sa njima povezanih stanja
JPWO2005012221A1 (ja) 2003-08-04 2006-09-14 小野薬品工業株式会社 ジフェニルエーテル化合物、その製造方法および用途
PT1660458E (pt) 2003-08-15 2012-04-27 Novartis Ag 2,4-pirimidinodiaminas úteis no tratamento de doenças neoplásicas, desordens inflamatórias e do sistema imunitário
ATE449069T1 (de) 2003-08-28 2009-12-15 Novartis Pharma Gmbh Aminopropanolderivate
US7825109B2 (en) 2003-08-29 2010-11-02 Ono Pharmaceutical Co., Ltd. Compound capable of binding S1P receptor and pharmaceutical use thereof
JP2007504230A (ja) 2003-09-02 2007-03-01 メルク　エンド　カムパニー　インコーポレーテッド ジペプチジルペプチダーゼ−ｉｖ阻害剤のリン酸塩の新規結晶性形態
WO2005023762A1 (fr) 2003-09-04 2005-03-17 Abbott Laboratories Derives de pyrrolidine-2-carbonitrile et leur utilisation comme inhibiteurs de la dipeptidyle peptidase-iv (dpp-iv)
TWI359147B (en) 2003-09-05 2012-03-01 Vertex Pharma Inhibitors of serine proteases, particularly hcv n
WO2005023771A1 (fr) 2003-09-05 2005-03-17 Ono Pharmaceutical Co., Ltd. Antagoniste du recepteur de la chimiokine et son utilisation a des fins medicales
EP1699777B1 (fr) 2003-09-08 2012-12-12 Takeda Pharmaceutical Company Limited Inhibiteurs de la dipeptidylpeptidase
EP1697342A2 (fr) 2003-09-08 2006-09-06 Takeda Pharmaceutical Company Limited Inhibiteurs de dipeptidyle peptidase
PE20050948A1 (es) 2003-09-09 2005-12-16 Japan Tobacco Inc Compuestos de carbamoil-amina como inhibidores de la dipeptidil peptidasa iv
CN1856307A (zh) 2003-09-23 2006-11-01 默克公司 喹啉钾通道抑制剂
EP1667524A4 (fr) 2003-09-23 2009-01-14 Merck & Co Inc Nouvelle forme cristalline d'un sel d'acide phosphorique d'un inhibiteur de dipeptidyle peptase-iv
US20070043014A1 (en) 2003-10-01 2007-02-22 Merck & Co., Inc. 3,5-Aryl, heteroaryl or cycloalkyl substituted-1,2,4-oxadiazoles as s1p receptor agonists
WO2005033099A2 (fr) 2003-10-03 2005-04-14 Glenmark Pharmaceuticals Ltd. Nouveaux inhibiteurs de dipeptidylpeptidase iv, leurs procedes de preparation et compositions les contenant
WO2005037215A2 (fr) 2003-10-14 2005-04-28 Massachusetts Institute Of Technology Compositions et procedes destines a ameliorer la fonction cognitive et la plasticite synaptique
GB0324236D0 (en) 2003-10-16 2003-11-19 Astrazeneca Ab Chemical compounds
TW200523252A (en) 2003-10-31 2005-07-16 Takeda Pharmaceutical Pyridine compounds
US7638637B2 (en) 2003-11-03 2009-12-29 University Of Virginia Patent Foundation Orally available sphingosine 1-phosphate receptor agonists and antagonists
WO2005044780A1 (fr) 2003-11-10 2005-05-19 Kyorin Pharmaceutical Co., Ltd. Derive d'acide aminocarboxylique, son sel d'addition et agent de regulation du recepteur s1p
AU2004289304A1 (en) 2003-11-10 2005-05-26 Synta Pharmaceuticals, Corp. Pyridine compounds
SG134333A1 (en) 2003-11-12 2007-08-29 Phenomix Corp Heterocyclic boronic acid compounds
MY141220A (en) 2003-11-17 2010-03-31 Astrazeneca Ab Pyrazole derivatives as inhibitors of receptor tyrosine kinases
WO2005058315A1 (fr) 2003-12-12 2005-06-30 Ribapharm, Inc. Nouveaux composes heterocycliques utilises comme inhibiteurs et presentant une activite anti-hbv
WO2005058849A1 (fr) 2003-12-15 2005-06-30 Glenmark Pharmaceuticals Ltd. Nouveaux inhibiteurs de dipeptidyle peptidase iv, leur procede de preparation et compositions les contenant
EP1697333A4 (fr) 2003-12-17 2009-07-08 Merck & Co Inc Carboxylates propanoiques 3,4-disusbstitues utilises en tant qu'agonistes du recepteur s1p (edg)
GB0329498D0 (en) 2003-12-19 2004-01-28 Novartis Ag Organic compounds
ATE528276T1 (de) 2003-12-19 2011-10-15 Ono Pharmaceutical Co Lysophosphatidylsäurerezeptor-antagonistische verbindungen und ihre anwendungen
DE10360835A1 (de) 2003-12-23 2005-07-21 Boehringer Ingelheim Pharma Gmbh & Co. Kg Bicyclische Imidazolverbindungen, deren Herstellung und deren Verwendung als Arzneimittel
JP4958560B2 (ja) 2003-12-24 2012-06-20 プロシディオン・リミテッド Ｇｐｃｒ受容体作動薬としてのヘテロ環誘導体
US20080227786A1 (en) 2004-01-16 2008-09-18 Ferlita Russell R Novel Crystalline Salts of a Dipeptidyl Peptidase-IV Inhibitor
GB0401332D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
WO2005075426A1 (fr) 2004-02-03 2005-08-18 Glenmark Pharmaceuticals Ltd. Nouveaux inhibiteurs de dipeptidyle peptidase iv, leur procedes de preparation et compositions en comportant
AU2005212438A1 (en) 2004-02-11 2005-08-25 Amgen Inc. Vanilloid receptor ligands and their use in treatments
TW200530236A (en) 2004-02-23 2005-09-16 Chugai Pharmaceutical Co Ltd Heteroaryl phenylurea
US7718704B2 (en) 2004-02-24 2010-05-18 Irm Llc Immunosuppressant compounds and compositions
TW200538433A (en) 2004-02-24 2005-12-01 Irm Llc Immunosuppressant compounds and compositiions
NZ549162A (en) 2004-02-24 2009-12-24 Sankyo Co Amino-pyrrol alcohol compounds
CN1934094A (zh) 2004-03-05 2007-03-21 万有制药株式会社 二芳基取代杂环5元环衍生物
GB0405289D0 (en) 2004-03-09 2004-04-21 Novartis Ag Organic compounds
GB0405933D0 (en) 2004-03-16 2004-04-21 Glaxo Group Ltd Compounds
JP5239071B2 (ja) 2004-04-02 2013-07-17 メルク・シャープ・アンド・ドーム・コーポレーション シクロアルカノインドール誘導体の調製のために有用な非対称水素化方法
EP1764367A1 (fr) 2004-04-12 2007-03-21 Sankyo Company, Limited Derivés de thienopyridine
WO2005117909A2 (fr) 2004-04-23 2005-12-15 Exelixis, Inc. Modulateurs des proteines kinases et leurs methodes d'utilisation
PL1756084T3 (pl) 2004-06-04 2009-06-30 Arena Pharm Inc Podstawione pochodne arylowe i heteroarylowe jako modulatory metabolizmu oraz profilaktyka i leczenie zaburzeń z metabolizmem związanych
WO2005123677A1 (fr) 2004-06-16 2005-12-29 Actelion Pharmaceuticals Ltd Utilisation de derives de 1,1,2-trimethyl-1a,4,5,5a-tetrahydro-1h-4-aza-cyclopropa[a]pentalene a substitution 4-carbonyle comme agonistes du recepteur couple aux proteines g s1p1/edg1 et agents immunosuppresseurs
JP5315611B2 (ja) 2004-06-23 2013-10-16 小野薬品工業株式会社 Ｓ１ｐ受容体結合能を有する化合物およびその用途
US7781617B2 (en) 2004-07-16 2010-08-24 Kyorin Pharmaceutical Co., Ltd Effective use method of medicaments and method of preventing expression of side effect
JP2007284350A (ja) 2004-07-27 2007-11-01 Takeda Chem Ind Ltd 糖尿病治療剤
WO2006010379A1 (fr) 2004-07-29 2006-02-02 Actelion Pharmaceuticals Ltd. Nouveaux derives du thiophene utilises comme agents immunosupresseurs
TW200611687A (en) 2004-07-29 2006-04-16 Sankyo Co Pharmaceutical compositions used for immunosuppressant
US8022225B2 (en) 2004-08-04 2011-09-20 Taisho Pharmaceutical Co., Ltd Triazole derivative
MX2007001661A (es) 2004-08-13 2007-04-23 Praecis Pharm Inc Metodos y composiciones para modular la actividad del receptor de esfingosina -1 fosfato (sip).
US20060223866A1 (en) 2004-08-13 2006-10-05 Praecis Pharmaceuticals, Inc. Methods and compositions for modulating sphingosine-1-phosphate (S1P) receptor activity
EP1827438B2 (fr) 2004-09-20 2014-12-10 Xenon Pharmaceuticals Inc. Derives de la piperazine et leur utilisation comme agents therapeutiques
WO2006034337A2 (fr) 2004-09-23 2006-03-30 Wyeth Derives de carbazole et de cyclopentaindole destines a traiter une infection par le virus de l'hepatite c
JP4797021B2 (ja) 2004-10-01 2011-10-19 メルク・シャープ・エンド・ドーム・コーポレイション 糖尿病の治療または予防用のジペプチジルペプチダ−ゼ−ｉｖ阻害剤としてのアミノピペリジン
US7557112B2 (en) 2004-10-08 2009-07-07 Astellas Pharma Inc. Aromatic-ring-fused pyrimidine derivative
CA2583947A1 (fr) 2004-10-12 2006-04-20 Forbes Medi-Tech (Research) Inc. Composes et methodes de traitement de la resistance insulinique et de la myocardiopathie
TW200621257A (en) 2004-10-20 2006-07-01 Astellas Pharma Inc Pyrimidine derivative fused with nonaromatic ring
PL1650186T3 (pl) 2004-10-22 2008-11-28 Bioprojet Soc Civ Nowe pochodne kwasów dikarboksylowych
CA2583681A1 (fr) 2004-10-22 2006-05-04 Merck & Co., Inc. Carboxylates, sulfonates, phosphonates, phosphinates 2-(aryl)azacyclylmethyle et heterocycles utilises comme agonistes des recepteurs s1p
AR051596A1 (es) 2004-10-26 2007-01-24 Irm Llc Compuestos heterociclicos condensados nitrogenados como inhibidores de la actividad del receptor canabinoide 1; composiciones farmaceuticas que los contienen y su empleo en la preparacion de medicamentos para el tratamiento de trastornos alimentarios
WO2006052566A2 (fr) 2004-11-03 2006-05-18 Arena Pharmaceuticals, Inc. Gpr41 et modulateurs de celui-ci utilises dans le traitement de troubles lies a l'insuline
GB0425035D0 (en) 2004-11-12 2004-12-15 Novartis Ag Organic compounds
JP2008520692A (ja) 2004-11-18 2008-06-19 ジ インスチチュート フォー ファーマシューティカル ディスカバリー、エルエルシー 複素環置換カルボン酸
JPWO2006057448A1 (ja) 2004-11-26 2008-06-05 武田薬品工業株式会社 アリールアルカン酸誘導体
WO2006063033A2 (fr) 2004-12-06 2006-06-15 University Of Virginia Patent Foundation Analogues d'aryl amide sphingosine 1-phosphate
BRPI0519012A2 (pt) 2004-12-13 2008-12-23 Ono Pharmaceutical Co derivado do Ácido aminocarboxÍlico e seu uso medicinal
BRPI0519006A2 (pt) 2004-12-13 2008-12-23 Daiichi Sankyo Co Ltd uso de um inibidor de fbpase, kit de uma composiÇço farmacÊutica, uso de uma preparaÇço de biguanida e um inibidor de fbpase, agente terapÊutico para diabetes melito, e, combinaÇço de agentes terapÊuticos
NZ556017A (en) 2004-12-24 2009-10-30 Prosidion Ltd G-protein coupled receptor (gpr116) agonists and use thereof for treating obesity and diabetes
EP1838706A1 (fr) 2004-12-24 2007-10-03 Prosidion Limited Agonistes du récepteur couplé aux protéines g
GB0428514D0 (en) 2004-12-31 2005-02-09 Prosidion Ltd Compounds
MY148521A (en) 2005-01-10 2013-04-30 Arena Pharm Inc Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto
DOP2006000008A (es) 2005-01-10 2006-08-31 Arena Pharm Inc Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1
DOP2006000010A (es) 2005-01-10 2006-07-31 Arena Pharm Inc Procedimiento para preparar eteres aromáticos
DOP2006000009A (es) 2005-01-13 2006-08-15 Arena Pharm Inc Procedimiento para preparar eteres de pirazolo [3,4-d] pirimidina
WO2006078992A2 (fr) 2005-01-19 2006-07-27 Neurogen Corporation Analogues de piperazinyl-pyridine à substitution hétéroaryle
DE112005003337T5 (de) 2005-01-25 2008-02-21 Merck Patent Gmbh Mesogene Verbindungen, Flüssigkristallmedium und Flüssigkristallanzeige
EP1685841A1 (fr) 2005-01-31 2006-08-02 Bayer Health Care Aktiengesellschaft Prevention et traitement de troubles thromboemboliques
US7754703B2 (en) 2005-02-14 2010-07-13 University Of Virginia Patent Foundation Cycloalkane-containing sphingosine 1-phosphate agonists
KR20080002850A (ko) 2005-03-23 2008-01-04 액테리온 파마슈티칼 리미티드 신규한 티오펜 유도체
CA2602474C (fr) 2005-03-23 2014-06-10 Actelion Pharmaceuticals Ltd Derives hydrogenes de benzo (c) thiophene utilises comme immunomodulateurs
US7605269B2 (en) 2005-03-23 2009-10-20 Actelion Pharmaceuticals Ltd. Thiophene derivatives as Sphingosine-1-phosphate-1 receptor agonists
WO2006131336A1 (fr) 2005-06-08 2006-12-14 Novartis Ag Oxadiazoles polycycliques ou soxazoles i et leur utilisation comme ligands recepteurs de s1p
US7951794B2 (en) 2005-06-24 2011-05-31 Actelion Pharmaceuticals Ltd. Thiophene derivatives
TWI418350B (zh) 2005-06-24 2013-12-11 Sankyo Co 含有ｐｐａｒ調節劑之醫藥組成物的用途
JP2008545010A (ja) 2005-06-30 2008-12-11 プロシディオン・リミテッド Ｇタンパク質共役受容体アゴニスト
JP5054004B2 (ja) 2005-07-01 2012-10-24 アイアールエム・リミテッド・ライアビリティ・カンパニー タンパク質キナーゼ阻害剤としてのピリミジン置換ベンゾイミダゾール誘導体
US20070060573A1 (en) 2005-08-10 2007-03-15 Lars Wortmann Acyltryptophanols
BRPI0615133A2 (pt) 2005-08-23 2011-05-03 Irm Llc compostos imunossupressores, composições farmacêuticas contendo os mesmos assim como referido uso
US20100160359A1 (en) 2005-09-16 2010-06-24 Arena Pharmaceuticals, Inc. Modulators of Metabolism and the Treatment of Disorders Related Thereto
TW200745055A (en) 2005-09-23 2007-12-16 Organon Nv 4-Phenyl-6-substituted-pyrimidine-2-carbonitrile derivatives
JPWO2007037196A1 (ja) 2005-09-29 2009-04-09 山本化成株式会社 インドリン系化合物及びその製造方法
PL1932522T3 (pl) * 2005-10-07 2012-09-28 Kyorin Seiyaku Kk Środek terapeutyczny do leczenia choroby wątroby zawierający jako składnik czynny pochodną 2-amino-1,3-propanodiolu
AR057894A1 (es) 2005-11-23 2007-12-26 Actelion Pharmaceuticals Ltd Derivados de tiofeno
EP1965807A4 (fr) 2005-11-23 2010-10-27 Epix Delaware Inc Composes modulateurs du recepteur s1p et utilisation associee
CA2635531C (fr) 2005-12-29 2014-06-17 Lexicon Pharmaceutical Inc. Derives d'acides amines multicycliques et procedes d'utilisation de ceux-ci
TWI404706B (zh) 2006-01-11 2013-08-11 Actelion Pharmaceuticals Ltd 新穎噻吩衍生物
TW200736234A (en) 2006-01-17 2007-10-01 Astrazeneca Ab Chemical compounds
PL1973884T3 (pl) 2006-01-19 2017-05-31 Orchid Pharma Limited Nowe związki heterocykliczne
AU2007209051A1 (en) 2006-01-24 2007-08-02 Actelion Pharmaceuticals Ltd Novel pyridine derivatives
GB0601744D0 (en) 2006-01-27 2006-03-08 Novartis Ag Organic compounds
TWI389683B (zh) 2006-02-06 2013-03-21 Kyorin Seiyaku Kk A therapeutic agent for an inflammatory bowel disease or an inflammatory bowel disease treatment using a 2-amino-1,3-propanediol derivative as an active ingredient
TW200806611A (en) 2006-02-09 2008-02-01 Daiichi Seiyaku Co Novel amidopropionic acid derivatives and medicine containing the same
JP2009526073A (ja) 2006-02-09 2009-07-16 ユニバーシティ オブ バージニア パテント ファンデーション 二環式スフィンゴシン−１−リン酸受容体アナログ
US20070191371A1 (en) 2006-02-14 2007-08-16 Kalypsys, Inc. Heterocyclic modulators of ppar
AU2007214434B2 (en) 2006-02-15 2012-06-14 Allergan, Inc. Indole-3-carboxylic acid amide, ester, thioamide and thiol ester compounds bearing aryl or heteroaryl groups having sphingosine-1-phosphate (S1P) receptor antagonist biological activity
CN101460458A (zh) 2006-02-15 2009-06-17 阿勒根公司 具有1－磷酸－鞘氨醇(s1p)受体拮抗剂生物活性的带芳基或者杂芳基基团的吲哚－3－羧酸的酰胺、酯、硫代酰胺和硫羟酸酯化合物
KR20080096780A (ko) 2006-02-21 2008-11-03 유니버시티 오브 버지니아 페이턴트 파운데이션 Ｓ１ｐ 수용체 효능제로서의 페닐-시클로알킬 및 페닐-헤테로시클릭 유도체
US7649098B2 (en) 2006-02-24 2010-01-19 Lexicon Pharmaceuticals, Inc. Imidazole-based compounds, compositions comprising them and methods of their use
MX2008011615A (es) 2006-03-14 2008-09-22 Amgen Inc Derivados de acidos carboxilicos biciclicos utiles para tratar trastornos metabolicos.
AU2007227274A1 (en) 2006-03-21 2007-09-27 Epix Delaware, Inc. S1P receptor modulating compounds
JP2007262009A (ja) 2006-03-29 2007-10-11 Dai Ichi Seiyaku Co Ltd ヘテロアリール低級カルボン酸誘導体
PL2003132T3 (pl) 2006-04-03 2014-10-31 Astellas Pharma Inc Pochodne oksadiazolu jako agoniści S1P1
US7833730B2 (en) 2006-04-11 2010-11-16 Arena Pharmaceuticals, Inc. Methods of using GPR119 to identify compounds useful for increasing bone mass in an individual
PE20071221A1 (es) 2006-04-11 2007-12-14 Arena Pharm Inc Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas
GB0607389D0 (en) 2006-04-12 2006-05-24 Novartis Ag Organic compounds
EP2258700A1 (fr) 2006-05-09 2010-12-08 Pfizer Products Inc. Dérivés d'acides aminés cycloalkyles et compositions pharmaceutiques les contenant
WO2007129473A1 (fr) 2006-05-09 2007-11-15 Daiichi Sankyo Company, Limited Dérivé arylique bicyclique
WO2007129745A1 (fr) 2006-05-09 2007-11-15 Daiichi Sankyo Company, Limited Derive acide carboxylique inferieur d'heteroarylamide
TW200811140A (en) 2006-07-06 2008-03-01 Arena Pharm Inc Modulators of metabolism and the treatment of disorders related thereto
TW200811147A (en) 2006-07-06 2008-03-01 Arena Pharm Inc Modulators of metabolism and the treatment of disorders related thereto
EP2043744A2 (fr) 2006-07-13 2009-04-08 SmithKline Beecham Corporation Composés chimiques
AR062156A1 (es) 2006-08-01 2008-10-22 Praecis Pharm Inc Compuestos agonistas y selectivos del receptor s1p-1
EP2046766A1 (fr) 2006-08-01 2009-04-15 Praecis Pharmaceuticals Incorporated Agonistes du récepteur du sphingosine - 1- phosphate (slp)
JP2009545630A (ja) 2006-08-04 2009-12-24 プリーシス・ファーマシューティカルズ・インコーポレイテッド 化合物
CA2659598A1 (fr) 2006-08-08 2008-02-14 Kyorin Pharmaceutical Co., Ltd. Derive d'ester de l'acide aminophosphorique et modulateur durecepteur s1p contenant ledit derive en tant que principe actif
EP2054377A1 (fr) * 2006-08-24 2009-05-06 Praecis Pharmaceuticals Incorporated Composés chimiques
JP2009269819A (ja) 2006-08-25 2009-11-19 Asahi Kasei Pharma Kk アミン化合物
WO2008025799A1 (fr) 2006-08-30 2008-03-06 Biovitrum Ab (Publ) Composés de pyridazine permettant de traiter les troubles liés à gpr119
PT2069336E (pt) 2006-09-07 2013-03-07 Actelion Pharmaceuticals Ltd Derivados de piridin-4-ilo como agentes imunomoduladores
CA2662852A1 (fr) 2006-09-07 2008-03-13 Allergan, Inc. Composes heteroaromatiques presentant une activite biologique agoniste et/ou antagoniste sur le recepteur sphingosine-1-phosphate (s1p)
AR061841A1 (es) 2006-09-07 2008-09-24 Actelion Pharmaceuticals Ltd Derivados de tiofen-oxadiazoles, agonistas del receptor s1p1/edg1, composiciones farmaceuticas que los contienen y usos como agentes inmunomoduladores.
KR20090060333A (ko) 2006-09-08 2009-06-11 노파르티스 아게 림프구 상호작용에 의해 매개되는 질환의 치료에 유용한 ｎ-바이아릴 (헤테로)아릴술폰아미드 유도체
ES2393412T3 (es) 2006-09-21 2012-12-21 Actelion Pharmaceuticals Ltd. Derivados de fenilo y su uso como inmunomoduladores
JP5330260B2 (ja) 2006-12-06 2013-10-30 スミスクライン ビーチャム コーポレーション 二環式化合物ならびに抗糖尿病薬としての使用
AU2007334519A1 (en) 2006-12-14 2008-06-26 Merck Sharp & Dohme Corp. Acyl bipiperidinyl compounds, compositions containing such compounds and methods of treatment
EP2109364A4 (fr) 2006-12-15 2010-04-14 Abbott Lab Composés d'oxadiazole innovants
JO2701B1 (en) 2006-12-21 2013-03-03 جلاكسو جروب ليميتد Vehicles
BRPI0720478A2 (pt) 2006-12-21 2014-01-14 Abbott Laboratoires Compostos agonistas e antagonistas do receptor esfingosina-1-fosfato
GB0625648D0 (en) 2006-12-21 2007-01-31 Glaxo Group Ltd Compounds
MX2009007334A (es) 2007-01-11 2009-07-15 Allergan Inc Compuestos de amida del acido indol-3-carboxilico 6-substituido que tienen actividad antagonista biologica del receptor esfingosina-1-fosfato (s1p).
WO2008091967A1 (fr) 2007-01-26 2008-07-31 Smithkline Beecham Corporation Composés chimiques
WO2008097819A2 (fr) 2007-02-05 2008-08-14 Smithkline Beecham Corporation Composés chimiques
BRPI0808789A2 (pt) 2007-03-16 2014-08-12 Actelion Pharmaceuticals Ltd Compostos e composição farmacêutica de derivados aminopiridina e uso destes
JP5191497B2 (ja) 2007-03-21 2013-05-08 エピックス ファーマシューティカルズ，インコーポレイテッド Ｓ１ｐ受容体調節化合物およびその使用
WO2008128832A1 (fr) 2007-04-18 2008-10-30 Nicox S.A. Nitrodérivés non peptidiques d'inhibiteurs de la rénine destinés au traitement de maladies cardiovasculaires, rénales et chroniques du foie, des inflammations et du syndrome métabolique
AU2008240773B2 (en) 2007-04-19 2013-10-03 Glaxo Group Limited Oxadiazole substituted indazole derivatives for use as sphingosine 1-phosphate (S1P) agonists
US7910583B2 (en) 2007-05-04 2011-03-22 Bristol-Myers Squibb Company [6,6] and [6,7]-bicyclic GPR119 G protein-coupled receptor agonists
EP2014653A1 (fr) 2007-06-15 2009-01-14 Bioprojet Nouveaux dérivés d'acide dicarboxylique comme agonistes du recepteur S1P1
WO2009011850A2 (fr) 2007-07-16 2009-01-22 Abbott Laboratories Nouveaux composés thérapeutiques
WO2009019506A1 (fr) 2007-08-03 2009-02-12 Astrazeneca Ab Sulfonamides hétérocycliques ayant une activité antagoniste de edg-1
CN101790519B (zh) 2007-08-08 2013-10-16 默克雪兰诺有限公司 用于治疗多发性硬化症的结合于鞘氨醇1-磷酸(s1p)的6-氨基-嘧啶-4-羧酰胺衍生物及相关化合物
BRPI0817211A2 (pt) 2007-09-20 2017-05-16 Irm Llc composto composições como moduladores da atividade de gpr119
TW200930368A (en) 2007-11-15 2009-07-16 Astrazeneca Ab Bis-(sulfonylamino) derivatives in therapy
US8637704B2 (en) 2007-11-28 2014-01-28 Synta Pharmaceuticals Corp. Polymorphs of N-malonyl-bis(N′-methyl-N′-thiobenzoylhydrazide)
EP2222668B1 (fr) 2007-12-18 2011-11-02 Arena Pharmaceuticals, Inc. Dérivés d'acide tétrahydrocyclopenta[b]indol-3-ylcarboxylique utiles dans le traitement de troubles auto-immuns et inflammatoires
EP2252615A1 (fr) 2008-01-25 2010-11-24 Arena Pharmaceuticals, Inc. Dérivés carboxyliques dihydro-1h-pyrrolo[1,2-a]indol-1-yle agissant comme des agonistes de s1p1
AR070398A1 (es) 2008-02-22 2010-03-31 Gruenenthal Chemie Derivados sustituidos de indol
US20110000153A1 (en) 2008-02-28 2011-01-06 Solar Roofing Systems, Inc. Photovoltaic Roofing Tile with Fire Suppression
PL2278960T5 (pl) 2008-03-17 2020-06-29 Actelion Pharmaceuticals Ltd. Schemat dawkowania dla selektywnego agonisty receptora sip1
EP2108960A1 (fr) 2008-04-07 2009-10-14 Arena Pharmaceuticals, Inc. Procédés d'utilisation d'un récepteur couplé à protéine G pour identifier les secrétagogues de peptide YY (PYY) et composés utiles dans le traitement des conditions modulées de secrétagogues BY (PYY) et composés utiles dans le traitement des conditions par PYY
EP2271619A1 (fr) 2008-04-07 2011-01-12 Irm Llc Composés et compositions servant de modulateurs de l activité de gpr119
WO2009125434A2 (fr) 2008-04-07 2009-10-15 Cadila Healthcare Limited Dérivés d’oxime
EP3782991A1 (fr) 2008-05-14 2021-02-24 The Scripps Research Institute Nouveaux modulateurs de récepteurs de la sphingosine phosphate
WO2009151621A1 (fr) 2008-06-13 2009-12-17 Arena Pharmaceuticals, Inc. Dérivés de l’acide (1, 2, 4-oxadiazol-3-yl)indolin-1-yl carboxylique substitué utiles comme agonistes de s1p1
WO2009151626A1 (fr) 2008-06-13 2009-12-17 Arena Pharmaceuticals, Inc. Dérivés de l’acide (1, 2, 4-oxadiazol-3-yl)indolin-1-yl carboxylique substitué pouvant être utilisés comme agonistes de s1p1
US8580841B2 (en) 2008-07-23 2013-11-12 Arena Pharmaceuticals, Inc. Substituted 1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid derivatives useful in the treatment of autoimmune and inflammatory disorders
HRP20160890T1 (hr) 2008-08-27 2016-09-23 Arena Pharmaceuticals, Inc. Derivati supstituirane tricikličke kiseline kao agonisti s1p1-receptora korisni u liječenju autoimunih i upalnih poremećaja
TW201028143A (en) 2008-12-22 2010-08-01 Novartis Ag Dosage regimen for a S1P receptor agonist
JP5657565B2 (ja) 2008-12-22 2015-01-21 ノバルティス アーゲー Ｓ１ｐ受容体アゴニストの投与レジメン
CA2747809A1 (fr) 2008-12-23 2010-07-01 Joel M. Harris Derives d'heterocycles bicycliques et leurs procedes d'utilisation
WO2010075273A1 (fr) 2008-12-23 2010-07-01 Schering Corporation Dérivés d'hétérocycles bicycliques et leurs procédés d'utilisation
WO2010074271A1 (fr) 2008-12-26 2010-07-01 武田薬品工業株式会社 Agent thérapeutique pour le diabète
US20120016119A1 (en) 2009-01-22 2012-01-19 Yasunori Tsuboi NOVEL PYRROLO(2,3-d)PYRIMIDINE COMPOUND
PE20120578A1 (es) 2009-02-10 2012-06-17 Abbott Lab Agonistas y antagonistas del receptor de s1p5, y metodos de uso de los mismos
WO2011005290A1 (fr) 2009-06-23 2011-01-13 Arena Pharmaceuticals, Inc. Dérivés d'oxadiazole disubstitués utiles dans le traitement de troubles auto-immuns et inflammatoires
WO2011005295A1 (fr) 2009-06-24 2011-01-13 Arena Pharmaceuticals, Inc. Modulateurs du récepteur sphingosine-1-phosphate (s1p) utiles pour le traitement de troubles associés à ceux-ci
AR077642A1 (es) 2009-07-09 2011-09-14 Arena Pharm Inc Moduladores del metabolismo y el tratamiento de trastornos relacionados con el mismo
AR077638A1 (es) 2009-07-15 2011-09-14 Lilly Co Eli Compuesto de (metanosulfonil -piperidin )-( alcoxi-aril) -tetrahidro- piridina , composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para el tratamiento de diabetes u obesidad
WO2011030139A1 (fr) 2009-09-11 2011-03-17 Astrazeneca Ab Derives de 4-(pyrimidin-2-yl)-piperazine et de 4-(pyrimidin-2-yl)-piperidine utilises en tant que modulateurs du gpr119
US9216972B2 (en) 2009-10-29 2015-12-22 Bristol-Myers Squibb Company Tricyclic heterocyclic compounds
US8299059B2 (en) 2009-10-30 2012-10-30 Eli Lilly And Company Crystalline compound and a process for its preparation
US8440693B2 (en) 2009-12-22 2013-05-14 Novartis Ag Substituted isoquinolinones and quinazolinones
CN102753543A (zh) 2009-12-30 2012-10-24 麦迪凯姆股份公司 药用用途的1-(1h-1,2,4-三唑-1-基)-2-丁醇衍生物，以及使用具有基本上未定义晶形的1-(1h-1,2,4-三唑-1-基)-2-丁醇衍生物制备所述1-(1h-1,2,4-三唑-1-基) -2-丁醇衍生物
JP5856980B2 (ja) 2010-01-27 2016-02-10 アリーナ ファーマシューティカルズ， インコーポレイテッド （Ｒ）−２−（７−（４−シクロペンチル−３−（トリフルオロメチル）ベンジルオキシ）−１，２，３，４−テトラヒドロシクロペンタ［ｂ］インドール−３−イル）酢酸およびその塩の調製のためのプロセス
CN105503882B (zh) 2010-03-03 2019-07-05 艾尼纳制药公司 制备s1p1受体调节剂及其晶体形式的方法
CA2795513A1 (fr) 2010-04-06 2011-10-13 Arena Pharmaceuticals, Inc. Modulateurs du recepteur de gpr119 et traitement de troubles associes
JP2013533286A (ja) 2010-07-30 2013-08-22 セントルイス ユニバーシティ 疼痛を治療する方法
EP3323818A1 (fr) 2010-09-22 2018-05-23 Arena Pharmaceuticals, Inc. Modulateurs du récepteur gpr119 et traitement de troubles associés
EA034451B1 (ru) 2011-02-07 2020-02-10 Байоджен Ма Инк. Модуляторы s1p
US20140018371A1 (en) 2011-04-01 2014-01-16 Arena Pharmaceuticals, Inc. Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
WO2012145361A1 (fr) 2011-04-19 2012-10-26 Arena Pharmaceuticals, Inc. Modulateurs du récepteur gpr119 et traitement de troubles liés à celui-ci
US20140038889A1 (en) 2011-04-22 2014-02-06 Arena Pharmaceuticals, Inc. Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
US20140051714A1 (en) 2011-04-22 2014-02-20 Arena Pharmaceuticals, Inc. Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
WO2012170702A1 (fr) 2011-06-08 2012-12-13 Arena Pharmaceuticals, Inc. Modulateurs du récepteur gpr119 et traitement de troubles associés à celui-ci
WO2013055910A1 (fr) 2011-10-12 2013-04-18 Arena Pharmaceuticals, Inc. Modulateurs du récepteur gpr119 et traitement de troubles associés
CN104093310A (zh) 2012-02-03 2014-10-08 泰华制药工业有限公司 拉喹莫德用于治疗一线抗TNFα疗法失败的克罗恩氏病患者的用途
US20160038506A1 (en) 2012-02-14 2016-02-11 Repros Therapeutics Inc. Selective Estrogen Receptor Modulators With Short Half-Lives and Uses Thereof
US8962888B2 (en) 2012-12-03 2015-02-24 Physical Sciences, Inc. Forming spherical crystal habit
JP5589110B1 (ja) 2013-03-08 2014-09-10 株式会社ポーラファルマ 晶癖を有する結晶及び該結晶を有効成分として含有する医薬組成物
PL3242666T3 (pl) 2015-01-06 2025-02-17 Arena Pharmaceuticals, Inc. Związek do zastosowania w leczeniu dolegliwości związanych z receptorem s1p1
BR112017027656B1 (pt) 2015-06-22 2023-12-05 Arena Pharmaceuticals, Inc. Hábito cristalino de placa livre de sal de l-arginina de ácido (r)-2-(7-(4- ciclopentil-3-(trifluorometil)benzilóxi)- 1,2,3,4-tetra-hidrociclo-penta[b]indol-3- il)acético, composição farmacêutica que o compreende, seus usos e método de preparação do mesmo
MX2019009843A (es) 2017-02-16 2020-01-30 Arena Pharm Inc Compuestos y metodos para el tratamiento de la enfermedad inflamatoria intestinal con manifestaciones extraintestinales.
MX2019009841A (es) 2017-02-16 2020-01-30 Arena Pharm Inc Compuestos y metodos para el tratamiento de la colangitis biliar primaria.
CA3102136A1 (fr) 2018-06-06 2019-12-12 Arena Pharmaceuticals, Inc. Methodes de traitement de troubles associes au recepteur s1p1<sb />
JP7265620B2 (ja) 2018-10-03 2023-04-26 アリーナ ファーマシューティカルズ， インコーポレイテッド 強皮症の治療のための方法
CN118649163A (zh) 2018-11-30 2024-09-17 艾尼纳制药公司 治疗与s1p1受体有关的病况的方法
CN113874009A (zh) 2019-01-08 2021-12-31 艾尼纳制药公司 治疗与s1p1受体有关的病况的方法

Also Published As

Publication number Publication date
AU2018220521A1 (en) 2019-09-05
MX2019009841A (es) 2020-01-30
US20230149353A1 (en) 2023-05-18
EP3582772A1 (fr) 2019-12-25
CA3053418A1 (fr) 2018-08-23
JP2020507611A (ja) 2020-03-12
KR20190116416A (ko) 2019-10-14
WO2018151873A1 (fr) 2018-08-23
US11534424B2 (en) 2022-12-27
US20200000770A1 (en) 2020-01-02
CN110520124A (zh) 2019-11-29

Similar Documents

Publication Publication Date Title
MA47504A (fr) Composés et méthodes de traitement de l&#39;angiocholite biliaire primitive
EP3458589A4 (fr) Compositions et méthodes de traitement de la maladie de huntington
MA50267A (fr) Compositions et méthodes de traitement de l&#39;amylose médiée par la transthyrétine (ttr)
EP3706737A4 (fr) Inhibiteurs de ash1l et méthodes de traitement comprenant ces derniers
EP3755351A4 (fr) Compositions et méthodes de traitement de l&#39;encéphalopathie mitochondriale neurogastro-intestinale
EP3607072A4 (fr) Compositions et méthodes de traitement de la phénylcétonurie
EP3775263A4 (fr) Compositions et méthodes de traitement de l&#39;acné
EP3390634A4 (fr) Compositions et méthodes pour le traitement de maladies oculaires
EP3298140A4 (fr) Compositions pour le traitement d&#39;états de calcification pathologique, et méthodes les utilisant
EP3411080A4 (fr) Composés et méthodes de traitement de maladies médiées par l&#39;arn
EP3423100A4 (fr) Compositions destinées à traiter l&#39;inflammation et méthodes de traitement associées
EP3589659A4 (fr) Composés et méthodes de traitement du cancer
EP3884053A4 (fr) Composés et méthodes permettant de réduire l&#39;expression de prion
MA53329A (fr) Méthodes de traitement de l&#39;épilepsie
EP3458079A4 (fr) Compositions et méthodes pour le traitement de l&#39;acné
EP3512524A4 (fr) Méthodes et compositions de traitement d&#39;infections virales
EP3634431A4 (fr) Compositions et méthodes thérapeutiques pour le traitement de l&#39;hépatite b
EP3405191A4 (fr) Méthodes et compositions pour le traitement de l&#39;hyperhidrose
EP3773633A4 (fr) Méthodes de traitement de glioblastomes
EP3383857A4 (fr) Composés et méthodes de traitement d&#39;infections bactériennes
MA51678A (fr) Méthodes de traitement de l&#39;amyotrophie musculaire
EP3773632A4 (fr) Méthodes de traitement de glioblastomes exprimant l&#39;egfrviii
EP3368048A4 (fr) Méthodes et compositions pour le traitement de l&#39;amyloïdose
EP3522865A4 (fr) Méthodes et compositions pour le traitement de vergetures
EP3400008A4 (fr) Compositions thérapeutiques et méthodes pour le traitement de l&#39;hépatite b